REPRESS Trial
Cross-source consensus on REPRESS Trial from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Comparisons
Other
Other
Highlighted claims
- REPRESS is a prospective multicentre open-label randomised controlled trial enrolling 212 ACS patients undergoing PCI. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- Participants are randomised equally to early PCSK9 inhibitor therapy plus moderate-intensity statin therapy or guideline-directed medical therapy. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- REPRESS tests whether adding an early PCSK9 inhibitor to moderate-intensity statin therapy stabilises non-culprit coronary plaques after acute coronary syndrome. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- The primary imaging treatment period lasts 6 months, with follow-up continuing to 12 months. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial
- The trial plans first enrolment in January 2026 and completion of analyses by January 2029. — PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial